POS-830 NEFECON FOR THE TREATMENT OF IgA NEPHROPATHY IN PATIENTS AT RISK OF PROGRESSING TO END-STAGE RENAL DISEASE: THE NEFIGARD PHASE 3 TRIAL RESULTS

• J. BARRATT,
• A. Stone,
• J. Kristensen

Affiliations

J. BARRATT

University of Leicester, Respiratory Sciences, Leicester, United Kingdom

A. Stone

Stone Biostatistics Ltd, Stone Biostatistics Ltd, Crewe, United Kingdom

J. Kristensen

Calliditas Therapeutics, Calliditas Therapeutics, Stockholm, Sweden